Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yi-Chang Liu

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
Bioorganic Chemistry|March 22, 2020
Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitorsAhmed K ElHady, Shou-Ping Shih, Yu-Cheng Chen, et al.
Scandinavian Journal of Infectious Diseases|December 7, 2006
Acute Q fever with hemophagocytic syndrome: case report and literature reviewTun-Chieh Chen, Ko Chang, Po-Liang Lu, et al.
The Kaohsiung Journal of Medical Sciences|November 23, 2006
Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single instituteHui-Hua Hsiao, Yi-Chang Liu, Hui-Jen Tsai, et al.
Scientific Reports|March 15, 2024
Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphomaShih-Feng Cho, Tsung-Jang Yeh, Hui-Ching Wang, et al.
The Kaohsiung Journal of Medical Sciences|May 4, 2006
Poor outcomes in patients with primary malignant mediastinal germ-cell tumorsHui-Hua Hsiao, Yi-Chang Liu, Hui-Jen Tsai, et al.
Molecular Carcinogenesis|July 3, 2013
MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinibYi-Chang Liu, Hui-Hua Hsiao, Wen-Chi Yang, et al.
Marine Drugs|July 29, 2020
13-Acetoxysarcocrassolide Exhibits Cytotoxic Activity Against Oral Cancer Cells Through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical ConceptsYi-Chang Liu, Bo-Rong Peng, Kai-Cheng Hsu, et al.
Journal of Clinical Medicine|September 9, 2023
Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic MalignanciesChien-Tzu Huang, Ching-Ping Lee, Tzu-Yin Chen, et al.
Anticancer Research|December 6, 2015
Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome in Acute LeukemiaMing-Yu Yang, Pai-Mei Lin, Hui-Hua Hsiao, et al.
Cancer Science|September 27, 2006
Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3Ming-Yu Yang, Jan-Gowth Chang, Pai-Mei Lin, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
Bioorganic Chemistry|March 22, 2020
Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitorsAhmed K ElHady, Shou-Ping Shih, Yu-Cheng Chen, et al.
Scandinavian Journal of Infectious Diseases|December 7, 2006
Acute Q fever with hemophagocytic syndrome: case report and literature reviewTun-Chieh Chen, Ko Chang, Po-Liang Lu, et al.
The Kaohsiung Journal of Medical Sciences|November 23, 2006
Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single instituteHui-Hua Hsiao, Yi-Chang Liu, Hui-Jen Tsai, et al.
Scientific Reports|March 15, 2024
Prognostic mutation signature would serve as a potential prognostic predictor in patients with diffuse large B-cell lymphomaShih-Feng Cho, Tsung-Jang Yeh, Hui-Ching Wang, et al.
The Kaohsiung Journal of Medical Sciences|May 4, 2006
Poor outcomes in patients with primary malignant mediastinal germ-cell tumorsHui-Hua Hsiao, Yi-Chang Liu, Hui-Jen Tsai, et al.
Molecular Carcinogenesis|July 3, 2013
MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinibYi-Chang Liu, Hui-Hua Hsiao, Wen-Chi Yang, et al.
Marine Drugs|July 29, 2020
13-Acetoxysarcocrassolide Exhibits Cytotoxic Activity Against Oral Cancer Cells Through the Interruption of the Keap1/Nrf2/p62/SQSTM1 Pathway: The Need to Move Beyond Classical ConceptsYi-Chang Liu, Bo-Rong Peng, Kai-Cheng Hsu, et al.
Journal of Clinical Medicine|September 9, 2023
Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic MalignanciesChien-Tzu Huang, Ching-Ping Lee, Tzu-Yin Chen, et al.
Anticancer Research|December 6, 2015
Up-regulation of PER3 Expression Is Correlated with Better Clinical Outcome in Acute LeukemiaMing-Yu Yang, Pai-Mei Lin, Hui-Hua Hsiao, et al.
Cancer Science|September 27, 2006
Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3Ming-Yu Yang, Jan-Gowth Chang, Pai-Mei Lin, et al.
Pageof 13